Form 4 for LGND LIGAND PHARMACEUTICALS INC
Accepted 2024-09-24 00:00:00 ET · period of report 2024-09-20 · accession 0002001011-24-000088 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2024-09-24 | 2024-09-20 | LGND | Espinoza Octavio | CFO | S - Sale | $103.94 | -1,275 | 25.4K | -5% | -$132.5K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-09-20 | S | D | 200 | $103.98 | 25,685 | D | — | — | |
| 2 | Common | Common Stock | 2024-09-20 | S | D | 800 | $103.95 | 24,610 | D | — | — | |
| 3 | Common | Common Stock | 2024-09-20 | S | D | 275 | $103.86 | 25,410 | D | — | — |